World Journal of Biology Pharmacy and Health Sciences
eISSN: 2582-5542
Cross Ref DOI: 10.30574/wjbphs
Journal homepage: https://wjbphs.com/

(REVIEW ARTICLE)

Evaluating the efficacy and safety of the Covishield vaccine: Balancing immune response and side effects in diverse populations

Dipendra Kohar [1,*], Bibek Kumar Das [1], Sulav Rawal [1], Bishnu Kohar [2], Modassir Hussain [3], Dipesh Yadav [4] and Vishal kajla [1]

[1] *College of pharmacy, RIMT UNIVERSITY, Mandigobindgarh, Punjab (147301), India.*
[2] *Aditya Bangalore Institute of pharmacy education and Research, Bangalore (560064) India.*
[3] *Maharajgunj Medical Campus, maharajgunj Kathmandu, Nepal.*
[4] *MMU College of Pharmacy, Ramanagar, Karnataka, India.*

World Journal of Biology Pharmacy and Health Sciences, 2024, 20(02), 029–036

Publication history: Received on 17 September 2024; revised on 26 October 2024; accepted on 28 October 2024

Article DOI: https://doi.org/10.30574/wjbphs.2024.20.2.0830

Abstract

The COVID-19 pandemic, which is attributed to the SARS-CoV-2 virus, has profoundly affected global health, especially among the elderly and those with preexisting health issues. In response to this crisis, the creation and distribution of effective vaccines have been vital. Covishield, a vaccine formulated by Oxford-AstraZeneca and produced by the Serum Institute of India, has been pivotalin the worldwide vaccination campaign. By utilizing viral vector technology, Covishield has demonstrated an efficacy rate of approximately 70% in preventing symptomatic COVID-19. Furthermore, it provides substantial protection against severe illness and hospitalization, even in the presence of emerging variants. This review aims to evaluate the efficacy, safety, and impact of Covishield across different demographic groups. Common side effects of the vaccine are generally mild, including pain at the injection site and low-grade fever. However, there have been rare reports of adverse events such as thrombosis with thrombocytopenia syndrome (TTS), which necessitate continuous monitoring and regulatory review. Despite these rare occurrences, Covishield remains an affordable option with manageable storage requirements, making it particularly valuable for low and middle-income countries. The review emphasizes the importance of ongoing survei lance, inclusive clinical trials, and transparent communication to address vaccine hesitancy. It also highlights the need for adaptation to new variants, equitable distribution of vaccines, and the integration of vaccination into broader public health strategies. The rapid development and distribution of Covishield underscore the significance of international cooperation and robust scientific methodologies in effectively addressing current and future global health emergencies.

Keywords: Covishield; COVID-19 vaccine; Vaccine efficacy; Safety profile; Immune response; Adverse effects

1. Introduction

Serious health repercussions have resulted from the ongoing COVID-19 pandemic, which was brought on by the SARS-CoV-2 virus. Specifically, older persons and those with pre-existing medical issues have had higher fatality rates [1,2]. The SARS-CoV-2 virus has had catastrophic effects on people all around the world, making it urgently necessary to produce and distribute effective vaccinations as soon as possible. Global Vaccination efforts have benefited greatly from one noteworthy vaccine, Covishield. Covishield, created by Oxford-AstraZeneca and produced by the Serum Institute of India, has become an essential weapon in the fight against the virus [3]. Utilizing a modified adenovirus to transfer genetic material encoding the SARS CoV-2 spike protein, Covershield uses viral vector technology to trigger an immune response without actually causing the illness[4].Studies on vaccine efficacy have demonstrated that Covishield is efficacious in preventing COVID-19, effectively reducing both the occurrence of symptomatic infections and the intensity

* Corresponding author: Dipendra Kohar.

of the illness [5]. It has garnered emergency use authorization in numerous nations and plays a crucial role, particularly in economies with limited resources, owing to its affordability and simpler storage prerequisites in contrast to mRNA vaccines [6]. The extensive implementation of Covershield presents a distinctive chance to examine its effectiveness among various populations. Available data indicates favorable protective outcomes across diverse demographic and ethnic groups [7]. Nevertheless, the safety of vaccines remains a critical issue. Continuous monitoring through post-marketing surveillance and clinical trials is essential to assess the safety of Covishield, with a particular focus on detecting any potential adverse effects. Typical Side effects may include mild to moderate symptoms like fever, fatigue, and localized pain following administration [8]. Additionally, there have been documented instances of uncommon yet severe adverse reactions, including thrombosis with thrombocytopenia syndrome (TTS), prompting thorough examinations and regulatory scrutiny [9].The global distribution of COVID-19 vaccines such as Bovishield presents a twofold challenge that goes beyond simply proving their effectiveness. It also requires guaranteeing their safety across diverse populations, while simultaneously striking a balance between immune response and minimizing potential adverse effects. This comprehensive analysis seeks to offer a thorough assessment of these factors, thereby contributing to the ongoing discussion surrounding vaccine implementation strategies and public health measures [10]. VACCINE EFFICACY The Covishield vaccine has exhibited notable effectiveness in the prevention of COVID-19, displaying a strong safeguarding impact against both the original virus strain and various variants. Comprehensive clinical studies have demonstrated that Covershield offers roughly a 70% protection against symptomatic SARS-CoV-2 infection after the completion of two doses[11]. This data is essential for understanding the vaccine's effectiveness in reducing the pandemic's impact, significantly lowering the chances of severe illness and hospitalization [12]. Furthermore, extensive research has been conducted to investigate the effectiveness of Covishield against different strains of the virus. This has become a significant area of focus, especially due to the emergence of variants that exhibit potential resistance to vaccines. Studies have indicated that although Covishield's neutralizing efficacy against some variants, such as the Beta(B.1.351) form that was initially discovered in South Africa, is somewhat reduced, it continues to offer significant protection against severe disease resulting from these variants[13]. The prevalence of these variants in certain regions has significant implications for global vaccination strategies [14].Covishield's capacity to adjust to shifting viral dynamics highlights its significance in the worldwide vaccine toolkit. Ongoing monitoring and investigation are essential to guarantee the ongoing effectiveness of vaccination efforts amidst the virus's mutations [15]. The continuous effectiveness research not only emphasizes Covishield's ability to decrease the burden of disease but also its capability to restrict virus spread, leading to wider public health advantages [16]. Table: 1. Comparative Analysis of Covishield Vaccine Effectiveness in Various Nations. Country Dosage Regimen Vaccine Efficacy (%) Reference India 2 doses(4-12 70.4% 17 weeks) United Kingdom 2 doses(4-12 weeks) 76% After 2nd dose 11 Brazil 2 doses(4-12 weeks) 62.3% 18 South Africa 2 doses(4-12 weeks) 10% to 22% against B.1.351 variant 19 Safety Profile of Covishield Understanding the overall impact of the Covishield vaccine heavily relies on comprehending its safety profile, as it significantly affects the public's trust in vaccine acceptance. Within this review article, we will delve into the various demographic groups and explore the spectrum of side effects encountered, shedding light on both prevalent and uncommon reactions. CommonSide Effects The commonside effects of the Covishield vaccine are comparable to those observed with other vaccines and are usually mild to moderate.Possible side effects may include discomfort at the injection site, feelings of fatigue, headaches, fever, as we las pain in the muscles or joints.Typically, these symptoms subside within a few days post vaccination. A research study conducted at various locations revealed that more than 60% of individuals who received the vaccine encountered pain at the injection site, while almost half reported experiencing headaches. [20]. Rare Reactions Mild side effects are possible with Covishield; nevertheless, rare reports of serious side effects have been made, including thrombocytopenia syndrome (TTS), particularly in younger women, with an incidence rate of 1caseper 250,000 doses administered [21]. Impact on Different Demographic Groups The safety profile of Covishield exhibits variability across different demographic groups, as older individuals tend to report a lower incidence of side effects, while women may encounter a slightly higher prevalence of fever-like symptoms [22]. It is crucial to note that current research efforts are persistently evaluating the extended term safety of Covishield among various demographic groups in order to avoid any potential risks that may be specific to certain populations. Special Considerations It is advisable for individuals with pre-existing conditions, especially those with a history of allergies or anaphylaxis, to seek advice from healthcare professionals prior to getting vaccinated because of the uncommon occurrence of allergic reactions [23]. Monitoring and Surveillance It is imperative to have post-vaccination surveillance systems in place for monitoring the safety of Covishield, detecting any unforeseen side effects, and revising protocols to guarantee the safety of all demographic groups [24]. Thrombosis With ThrombocytopeniaSyndrome (TTS):-Adenovirus vector vaccines, such as theCovishield (ChAdOx1nCoV-19)vaccine, have been linked to rare but dangerous illness known as thrombosis with thrombocytopenia syndrome (TTS).TTSis characterized by atypical blood clot formation along with decreased platelet count, typically manifesting within a defined period following vaccination. Clinical Presentation and Epidemiology TTSinstances commonly manifest symptoms within a timeframe of 4 to 30 days post vaccination, impacting atypical areas such as cerebral veins of the splanchnic region, while also potentially affecting more conventional sites like veins in the legs [25]. Based on data from the UK, the epidemiological evidence indicates that the occurrence rate of TTS following Covershield vaccination is approximately 1 in 250,000 vaccinations [26]. Pathophysiology The process of

TTSentails an immune reaction that generates antibodies targeting platelet factor 4 (PF4), a protein crucial for blood clotting. This immune response bears resemblance to heparin-induced thrombocytopenia(HIT), yet it transpires even in the absence of heparin exposure. The antibodies directed against PF4 trigger the activation of platelets, thereby resulting in the occurrence of thrombosis and thrombocytopenia[27]. Risk Factors and Demographics Although the likelihood of developing TTS is very low overall, it appears to be more prevalent among younger women. Nevertheless, the underlying cause of this increased risk in this particular demographic is not yet fully comprehended. Ongoing research and inquiries are being conducted to elucidate the potential genetic or biological factors that may play a role in this risk [28]. Diagnosis and Treatment Timely diagnosis of TTS is crucial, particularly in individuals who have received the COVID-19 vaccine. Essential Diagnostic tests encompass a full blood count, PF4-heparin ELISA, and various imaging studies [29]. The therapy includes the administration of non-heparin anticoagulants and high-dose intravenous immunoglobulin (IVIG) in order to inhibit antibody-mediated platelet activation [30]. Regulatory and Health Policy Responses In light of the TTS reports, numerous countries' health regulators have released guidelines advising the administration of alternative COVID-19 vaccines to high-risk populations, including younger women. Additionally, they have emphasized the importance of closely monitoring symptoms that may indicate following the administration of Covishield [31]. Table:2 Reported Deaths from TTS Following Covershield Vaccination by Country Country Reported Deaths from TTS Reference Germany 12 32 United Kingdom 73 33 Canada 5 34 France 6 35 Immune Response Mechanism of Covishield In order to express the SARS-CoV-2 spike protein and trigger an immune response without actually causing the disease, the Covishield vaccine uses genetically altered chimpanzee adenovirus, ChAdOx1[37]. The human immune system reacts to the injection of the SARS-CoV-2 spike protein because it perceives it as a foreign material and mounts an attack. Antigen-presenting ce ls (APCs), which collect the spike protein and display it to T lymphocytes on their surface, are activated in this method [38]. This presentation is important because it promotes the growth of Tcels, which include cytotoxic T ce ls that can eradicate virus-infected ce ls and helper T ce ls that aid in the activation of B ce ls [39]. B ce ls are simultaneously stimulated to develop into plasma ce ls, which particularly generate antibodies that target SARS-CoV-2 spike protein. These antibodies are vital for neutralizing the virus by preventing its attachment and entry into human cels, thereby averting infection [40].Furthermore, the immune response also encompasses the generation of memory cels, which guarantees that the immune system can promptly react to future encounters with the virus, providing enduring immunity [41]. Population Studies: Performance of Covishield Across Diverse Populations The comprehensive impact and guidance of vaccination strategies for the Bovishield vaccine have been assessed by considering a wide range of populations, encompassing different age groups, individuals with pre-existing conditions, and diverse ethnic backgrounds. This evaluation of efficacy and safety is of utmost importance in order to comprehend the vaccine's overall effectiveness and ensure appropriate vaccination approaches. Age Groups Clinical trials and real-world evidence have provided evidence that the Covishield vaccine is efficacious in adult age groups, albeit with slight variations in efficacy. The vaccination demonstrated an around 70% effectiveness rate in preventing adult COVID-19 infections in the early trials. It is particularly noteworthy that there were no reports of severe illness among older adults (aged over 65)after receiving the vaccine [11]. Furthermore, subsequent analysis specifically targeting elderly populations reaffirmed the vaccine's favorable safety profile and effectiveness, even among individuals who are typically considered at heightened risk for severe diseases [12]. In those with preexisting medical disorders such as diabetes, high blood pressure, and cardiovascular illnesses, Covishield shows efficacy and safety, stimulating a robust immune response that protects against these coexisting conditions [13]. Ethnic Background Covershield trials in the UK, Brazil, and South Africa showed consistent efficacy across ethnic groups, with some variations in immune response metrics. South Africa's study during Betavariant surge showed reduced efficacy [42]. Table: 3. Covishield's Efficacy in Varied Demographics. Population Group Efficacy / Safety Data Reference Adult Age Groups Elderly (>65 years) Approx. 70% efficacy in preventing COVID-19 infection Good efficacy, no severe disease post-vaccination Individuals with Pre-existing Conditions Safe and effective; robust immune response Different Ethnic Backgrounds Efficacy varies slightly, generally consistent 11 12 13 42 The comprehensive analysis of Covishield's Efficacy among various populations highlights its significance as a key component in the worldwide vaccination campaign, offering substantial defense for a broad spectrum of demographic categories, albeit displaying some discrepancies in effectiveness against specific strains. Advancing GlobalImmunity: The Importance of the ChAdOx1nCoV-19 (AZD1222) Vaccine in Combating the COVID-19 Epidemic": Despite the fact that the virus has become widespread globally, significant proportion of people in various countries are believed to be uninfected and so do not have protection to SARS-CoV-2. In order to solve the current health crises, lower the incidence of severe disease, and increase community immunity, vaccine development and assessment are crucial. The SARS-CoV-2 vaccine program has been developed quickly and thoroughly, which has resulted in an extraordinary number of vaccine candidates starting clinical trials in 2020. There are 48 vaccines undergoing clinical study at this time. [43]. Several Vaccines have demonstrated promising safety and immunogenicity characteristics, with 11 currently in phase 3 clinical trials to assess their effectiveness. The Oxford University-developed ChAdOx1nCoV-19 vaccine (AZD1222) is one prominent example. The SARS-CoV-2 spike protein antigen (nCoV-19)gene is carried by the chimpanzee adenovirus vector ChAdOx1, which is replication-deficient. On April 23, 2020, clinical studies for this vaccine started in the UK (COV001). Subsequent trials were conducted in the UK (COV002), Brazil(COV003), and South Africa (COV005). Furthermore, aphase 1/2 experiment

has commenced in Kenya; however, this publication does not furnish particulars. The phase 1/2 UK research COV001, which included 1,077 adults in good health ages 18 to 55, and the second phase group in COV002, which concentrated on older persons (age 56 and above), have released the results of their immunogenicity evaluations. These findings show that the vaccination has a good safety profile and that binding and neutralizing antibodies as well as interferon-γ enzyme-linked immunospot responses can be produced. Moreover, after the vaccination was given a second time, higher antibody levels were seen [44,45,46,47]. POTENTIAL HEART-RELATED SIDE EFFECTS OF COVERSHIELD Myocarditis and Pericarditis Link Post-vaccination, myocarditis and pericarditis have been reported, primarily with mRNA COVID-19 vaccines, but also with viral vector vaccines like Covershield, potentially leading to cardiac complications [48]. Mechanisms The cause of myocarditis or pericarditis post-vaccination is not fully understood, with hypothesized vaccine-induced immune response targeting cardiac ce ls, but specific pathways are still under investigation [49]. Safe vaccine is necessary to prevent from disease and ADR: Asof the end of 2021 on July 31, 14.5% of people worldwide had received al recommended vaccinations, while 28.8% had at least a single administration of the COVID-19 vaccine.This amounts to a total of 4.11billion doses administered, with an average of 37.58 million doses given each day [50]. While these figures are encouraging and suggest progress towards ending the pandemic, recent research reveals that there remains a segment of the population that is reluctant to get vaccinated [51].It remains a challenge to reach the most vulnerable population worldwide, persuade them about the efficacy of vaccines, and instill trust in vaccine developers [52]. Research conducted indicates that 27% of the American population would refuse to receive the COVID-19 vaccination, even in the scenario where it is provided at no cost and endorsed as safe by experts [53].The public's widespread and visible concern regarding the COVID-19 vaccine's quick development has been a major contributing factor to vaccination hesitancy [54]. Recently, hesitance towards the COVID-19 vaccine has been linked to worries about safety and possible side effects, along with a widespread distrust in both the vaccine itself and governmental entities, which intensifies concerns about vaccination [55]. In addition to establishing the vaccine's efficacy, it is crucial to foster public confidence in the COVID-19 vaccine and the immunization procedure, even though these worries are reasonable and understandable.[56]. It is crucial to emphasize that the expedited development of the vaccines does not indicate any compromise on safety protocols. The advancements achieved were the result of thorough research, extensive global collaboration among scientists, and significant financial investment [57]. The pandemic's urgency prompted increased funding for vaccine development in order to combat its consequences as soon as possible, which in turn enabled the mobilization of more financial and professional resources for the development of vaccines. [58].

2. Conclusion

The creation of the Covishield vaccine, accomplished through swift yet meticulous scientific endeavors, is an essential part of the global effort to combat the COVID-19 epidemic. Its creation and widespread distribution among diverse populations signify a significant milestone in public health. Covishield has proven to be highly effective in preventing COVID-19 infections, lessening the severity of the illness, and thereby easing the burden on healthcare systems worldwide. The benefits of vaccination exceed any potential hazards, even in the event that new risks arise— such as rare cases of thrombosis with thrombocytopenia syndrome (TTS)—when it comes to the vaccine. This is especially important considering the severe complications linked to COVID-19 itself, including direct impacts on cardiovascular health. The implementation of the vaccine has not only yielded promising outcomes in controlling the virus's transmission but has also provided valuable insights into vaccine safety and efficacy across various demographic groups, including individuals with pre existing health conditions and diverse ethnic backgrounds. These discoveries underscore the significance of inclusive clinical trials and post-market monitoring to ensure comprehensive data on safety and efficacy.

Future prospective

Ongoing assessment is necessary to determine the effectiveness of Covishield against emerging virus variants. The capacity to alter and refine vaccine formulations will be essential in maintaining the effectiveness of the global vaccination initiative.

Prioritizing fair access to the vaccine in low- and middle-income nations is of utmost importance. Overcoming logistical hurdles and bolstering production capabilities are key to achieving widespread immunization coverage and attaining global herd immunity.

It is essential to tackle vaccine hesitancy head-on. Open and honest communication along with active community involvement are essential in establishing public confidence. Providing transparent, evidence-based information regarding the advantages and drawbacks of vaccination can help alleviate concerns about the swift development and approval processes. √ Continuous Monitoring is vital for detecting any adverse events and ensuring long-term efficacy.

This involves monitoring the duration of immunity conferred by the vaccine and the potential necessity for booster shots. Such data will inform ongoing public health strategies and vaccination plans.

Vaccines Should be integrated into a comprehensive public health approach that includes ongoing testing, contact tracing, and the maintenance of personal protective measures until global herd immunity is reached. This holistic strategy will be crucial in managing outbreaks and curbing transmission. The COVID-19 crisis has presented unparalleled challenges but has also led to remarkable scientific progress.The knowledge acquired from the swift development, evaluation, and dissemination of vaccines like Covershield will certainly shape future strategies for addressing global health crises. As the world persists in its battle against the pandemic, promoting international collaboration and maintaining rigorous scientific standards will be crucial for defeating the virus and equipping ourselves for potential future pandemics.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

Reference

[1] COVIDTS. TedaviRehberi[İnternet][erişim 05 Nissan 2020] https://covid HYPERLINK "https://covid19bilgi/"19 HYPERLINK "https://covid19bilgi/"bilgi. saglik. gov. tr/depo/rehberler. COVID-19_Rehberi. pdf. 19.

[2] ZhouF, YuT, DuR, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: retrospective cohort study. The lancet. 2020 Mar 28;395(10229):1054-62.

[3] S.P.Jadhav et al., "Challenges in the development of an effective COVID-19 vaccine," Clinical & Experimental Vaccine Research, vol. 10, no. 1, pp. 114-124, Jan. 2021.

[4] V.N.Rauch et al., "Technology behind adenovirus-based vaccines: from design to production," Viruses, vol. 13, no. 6, Article no. 1112, Jun. 2021.

[5] Voysey M, ClemensSA, Madhi SA, WeckxLY, FolegattiPM, Aley PK, AngusB, Bai lie VL, Barnabas SL, Bhorat QE, Bibi S. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021 Jan 9;397(10269):99-111.

[6] Dal-Ré R.The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans. Therapies. 2023 May 1;78(3):293-302.

[7] M.Ramasamy et al., "Population-based studies of Covishield's Efficacy against COVID-19," Epidemiol. Infect., vol. 149, Article e82, 2021.

[8] E.A.Sheldon et al., "Adverse reactions of the ChAdOx1nCoV-19 coronavirus vaccine (recombinant)," Vaccine, vol. 39, no. 22, pp. 3082-3085, May 2021.

[9] Jain N, Chaudhary P, Shrivastava, Kaur T, Kaur S, Brar HS, JindalR. Thrombosis with ThrombocytopeniaSyndrome (TTS)After ChAdOx1nCoV-19 Immunization: An Investigative Case Report. The American Journal Of Case Reports. 2023;24:e938878-1.

[10] Yamey G, SchäferhoffM, Hatchett R, Pate M, Zhao F, McDade KK. Ensuring global access to COVID-19 vaccines. The Lancet. 2020 May 2;395(10234):1405-6.

[11] Voysey M, ClemensSA, Madhi SA, WeckxLY, FolegattiPM, Aley PK, Angus B, Bai lie VL, Barnabas SL, Bhorat QE, Bibi S. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021 Jan 9;397(10269):99-111.

[12] Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, Belij Rammerstorfer S, Bibi S, Bittaye M, CappucciniF, Cicconi P. Reactogenicity and immunogenicity after alate second dose or third dose of ChAdOx1nCoV-19 in the UK: a substudy of two randomized controlled trials (COV001and COV002). The Lancet. 2021 Sep 11;398(10304):981-90.

[13] Madhi SA, Bailie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, DhedaK, Barnabas SL, Bhorat QE, Briner C. Efficacy of the ChAdOx1nCoV-19 Covid-19 vaccine against the B. 1.351variant. New England Journal Of Medicine. 2021 May 20;384(20):1885-98.

[14] Schmidt F, Mueksch F, Weisblum Y, DaSilvaJ, BednarskiE, Cho A, Wang Z, Gaebler C, Caskey M, Nussenzweig MC, Hatziioannou T. Plasma Neutralization of the SARS-CoV-2 Omicron variant. New England Journal Of Medicine. 2022 Feb 10;386(6):599-601.

[15] World Health Organization. Weekly epidemiological update on COVID-19-1June 2021[Internet]. WHO; 2021.

[16] Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L. NovelSARS-CoV-2 variants: the pandemics within the pandemic. ClinicalMicrobiology and Infection. 2021 Aug 1;27(8):1109-17.

[17] Madhi SA, Bailie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, DhedaK, Barnabas SL, Bhorat QE, Briner C. Efficacy of the ChAdOx1nCoV-19 Covid-19 vaccine against the B. 1.351variant. New England Journal Of Medicine. 2021 May 20;384(20):1885-98.

[18] Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, NeuzilKM, Hahn W, Hunt J, Muligan MJ, McEvoy C.Phase 3 safety and efficacy of AZD1222 (ChAdOx1nCoV-19)Covid-19 vaccine. New England Journal Of Medicine. 2021 Dec 16;385(25):2348-60.

[19] S. J. Shinde et al., “Efficacy of ChAdOx1nCoV-19 (AZD1222)Vaccine Against SARS-CoV-2 Variant B.1.351(Beta),”medRxiv,2021.

[20] Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, Coyle P, AlKanaaniZ, AlKuwari E. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. Jama. 2021 Nov 16;326(19):1930-9.

[21] Schultz NH, SørvolIH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, WiedmannM, Aamodt AH, Skattør TH, Tjønnfjord GE, Holme PA. Thrombosis and thrombocytopeniaafter ChAdOx1nCoV-19 vaccination. New England journal of medicine. 2021 Jun 3;384(22):2124-30.

[22] P. English et al., "Demographic and clinical factors associated with COVID-19 vaccine hesitancy and side effects: A nationwide survey," Lancet Public Health, vol. 6, no. 5, pp. e404-e414, May 2021.

[23] Castels MC, Philips EJ. Maintaining safety with SARS-CoV-2 vaccines. New England Journalof Medicine. 2021 Feb 18;384(7):643-9.

[24] Food E.COVID-19 vaccines safety surveillance guideline.

[25] Scully M, Singh D, LownR, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, ThomasW, Lester W.Pathologicantibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. New England Journal Of Medicine. 2021 Jun 10;384(23):2202-11.

[26] MHRA."UKpublicassessment report for COVID-19 Vaccine AstraZeneca, regulation 174." Medicines & Healthcare products Regulatory Agency, 2021. [Link] (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/ attachment_data/file/978508/ UKPAR_COVID-19_Vaccine_AstraZeneca_05.04.2021.pdf) 27. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopeniaafter ChAdOx1nCov-19 vaccination. New England Journal of Medicine. 2021 Jun 3;384(22):2092-101.

[27] Cines DB, BusselJB. SARS-CoV-2 vaccine–induced immune thrombotic thrombocytopenia. New England Journal Of Medicine. 2021 Jun 10;384(23):2254-6.

[28] Pavord S, Sculy M, Hunt BJ, Lester W, Bagot C, Craven B, RampotasA, Ambler G, Makris M. Clinical Features of vaccine-induced immune thrombocytopenia and thrombosis. New England Journal Of Medicine. 2021 Oct 28;385(18):1680-9.

[29] Oldenburg J, Klamroth R, Langer F, Albisetti M, Von Auer C, Ay C, Korte W, Scharf RE, Pötzsch B, Greinacher A. Diagnosis and management of vaccine related thrombosis following AstraZenecaCOVID-19 vaccination: guidance statement from the GTH.Hämostaseologie. 2021 Jun;41(03):184-9.

[30] Dal-Ré R. The winding 12-month journey of the AstraZenecaCOVID-19 vaccine since its first administration to humans. Therapies. 2023 May 1;78(3):293-302.

[31] Paul-Ehrlich-Institut, "Safety of COVID-19 vaccines," 2021. Available: [pei.de] (https://www.pei.de/EN/newsroom/dossier/coronavirus/coronavirus content.html;jsessionid=3D15C7D4F1EAF9D5C799D1F1A8A223D2.intranet241)

[32] MHRA (Medicines And Healthcare products Regulatory Agency), "COVID-19 vaccine AstraZenecaanalysis print," 2021. Available: [MHRA.gov.uk](https:// www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse reactions/coronavirus-vaccine-summary-of-ye low-card-reporting)

[33] Health Canada, "Detailed report on COVID-19 vaccine side effects," 2021. Available: [canada.ca](https://www.canada.ca/en/health-canada/services/drugs health-products/covid19-industry/drugs-vaccines-treatments/vaccines.html)

[34] Cavalié P, Falip E, BruneauxF. ANSM–Agence Nationale de Sécurité du Médicament et desProduitsdeSanté. Analyse des ventes de médicaments en France en. 2011:21.

[35] Van DoremalenN, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato VA, Bushmaker T, Flaxman A, UlaszewskaM, Feldmann F. ChAdOx1nCoV-19 vaccine prevents SARS-CoV-2 pneumoniain rhesus macaques. Nature. 2020 Oct;586(7830):578-82.

[36] Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C. Safety and immunogenicity of the ChAdOx1nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. The Lancet. 2020 Aug 15;396(10249):467-78.

[37] Lin A, ApostolovicD, Jahnmatz M, Liang F, Ols S, Tecleab T, Wu C, Van HageM, Solovay K, Rubin K, Locht C. Live attenuated pertussis vaccine BPZE1induces a broad antibody response in humans. The Journalof clinical investigation. 2020 May 1;130(5):2332-46.

[38] Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, MakinsonR, Morter R, Flaxman A, Wright D, Belamy D, Bittaye M, Dold C. Tceland antibody responses induced by a single dose of ChAdOx1nCoV-19 (AZD1222)vaccine in aphase 1/2 clinical trial. Nature medicine. 2021 Feb;27(2):270-8.

[39] S.Jalkanenet al., "Antibody responses after adenovirus-vectored COVID-19 vaccination," Journal of Infectious Diseases, 2021. [Link](https:// academic.oup.com/jid/article/224/5/771/6279075)

[40] Poland GA, OvsyannikovaIG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. The Lancet. 2020 Nov 14;396(10262):1595-606. 42. M.Ramasamy et al., "Population-based age-stratified analysis of Covishield efficacy," Vaccine, vol. 39, no. 10, pp. 1441-1449, 2021.

[41] Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, BayssonH, De Ridder D, Petrovic D, Schrempft S, Marcus K, Yerly S. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. The Lancet. 2020 Aug 1;396(10247):313-9.

[42] World Health Organization. Draft Landscape of COVID-19 Candidate Vaccines 20 April 2020; 2020.

[43] Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Belamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C. Safety and immunogenicity of the ChAdOx1nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. The Lancet. 2020 Aug 15;396(10249):467-78.

[44] Prashob GR. A SYSTEMIC REVIEW ON SAFETY OF COVID 19 VACCINES AVAILABLE TODAY.

[45] Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, Halkerston R, HilJ, Jenkin D, Stockdale L, VerheulMK. Phase 1/2 trials of SARS CoV-2 vaccine ChAdOx1nCoV-19 with a booster dose induces multifunctional antibody responses. Nature medicine. 2021 Feb;27(2):279-88.

[46] F.K.Swaminathan et al., "COVID-19 Vaccine-Associated Myocarditis and Pericarditis in Young Adults: A Systematic Review and Meta-analysis," Journal Of Cardiovascular Development and Disease, vol. 9, no. 3, pp. 73, 2022. [PubMed] (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954345/)

[47] M.Caforioet al., "Autoimmunity and Myocarditis: Molecular Mechanisms of Disease and Vaccine Induced Immune Mediated Heart Failure," Circulation Research, vol. 128, no. 12, pp. 1724-1746, 2021. [Circulation Research](https:// www.ahajournals.org/doi/10.1161/CIRCRESAHA.121.318060)

[48] Post LA, Wu SA, SoetiknoAG, Ozer EA, Liu Y, Welch SB, HawkinsC, MossCB, Murphy RL, Mason M, Havey RJ.Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023)in Latin America And the Caribbean: Longitudinal Trend Analysis. JMIRPublic Health and Surveillance. 2024 May 17;10:e44398.

[49] Soucheray S. 1in 5 Americans say they won't get COVID-19 vaccine [Internet]. Minneapolis (MN): Center for Infectious Disease Research and Policy; 2021[cited 2021Jul31]. Available from: https://www.cidrap.umn.edu/newsperspective/ HYPERLINK "https://www.cidrap.umn.edu/newsperspective/2021/04/1-5 americans-say-they-wont-getcovid-19-vaccine"2021HYPERLINK"https:// www.cidrap.umn.edu/newsperspective/2021/04/1-5-americans-say-they-

wont getcovid-19-vaccine"/HYPERLINK"https://www.cidrap.umn.edu/ newsperspective/2021/04/1-5-americans-say-they-wont-getcovid-19vaccine"04 HYPERLINK "https://www.cidrap.umn.edu/newsperspective/ 2021/04/1-5-americans-say-they-wont-getcovid-19-vaccine"/HYPERLINK"https:// www.cidrap.umn.edu/newsperspective/2021/04/1-5-americans-say-they-wont getcovid-19-vaccine"1-5HYPERLINK"https://www.cidrap.umn.edu/ newsperspective/2021/04/1-5-americans-say-they-wont-getcovid-19-vaccine" americans-say-they-wont-getcovid-HYPERLINK"https://www.cidrap.umn.edu/ newsperspective/2021/04/1-5-americans-say-they-wont-getcovid-19-vaccine"19 HYPERLINK"https://www.cidrap.umn.edu/newsperspective/2021/04/1-5 americans-say-they-wont-getcovid-19-vaccine"-vaccine.

[50] CasselDK. How conspiracy theories undermine trust of COVID-19 vaccines. Healthline [Internet]. 2021 Feb 2 [cited 2021Jul31]. Available from: https:// www.healthline. com/health-news/how-conspiracy-theories-underminepeoples trust-in-covid-19-vaccines.

[51] Salmon, D., Opel, D.J., Dudley, M.Z., Brewer, J. and Breiman, R., 2021. Reflections On Governance, Communication, And Equity: ChalengesAnd Opportunities In COVID-19 Vaccination: Article examines the engagement and communication steps necessary to strengthen the COVID-19 vaccine rollout by federal, state, and local governments. Health Affairs, 40(3), pp.419-425.

[52] NuwardaRF, Ramzan I, WeekesL, Kayser V. Vaccine hesitancy: contemporary issues and historical background. Vaccines. 2022 Sep 22;10(10):1595.

[53] COVID-19 updates: getting your COVID-19 vaccine [Internet]. Dearborn (MI): Beaumont; 2021[cited 2021Aug 1]. Available from: https://www.beaumont.org/ covvaccine.

[54] Brown R.COVID-19 and InternationalPoliticalTheory: Assessing the Potential For Normative Shift. Springer Nature; 2022 Feb 14.

[55] Lamptey E.Post-vaccination COVID-19 deaths: a review of available evidence and recommendations for the global population. Clinical And Experimental Vaccine Research. 2021 Sep;10(3):264.

[56] LeggeDG, Kim S.Equitable access to COVID-19 vaccines: cooperation around research and production capacity is critical. Journal For Peace and Nuclear Disarmament. 2021 Mar 5;4(sup1):73-134.

Authors short Biography

Mr. Dipendra Kohar (B.pharm), currently working as a research intern at Oniosome pvt.ltd and Published more than 5 review articles in a national and international (Scopus) Journal and also published a book on chapter colloidal dispersion.